Omega-3 / Fish Oil for Cardiovascular Disease

Verdict: Weak, conflicting evidence; depends on dose and population

For the general public taking ordinary fish-oil supplements, omega-3s have not been shown to prevent cardiovascular disease. A clear benefit appears only in a narrow high-risk group using prescription-grade purified EPA, and even then the trial evidence is contradictory.

C 🟠 C Weak Evidence Disputed

🔬Why this grade7-layer evidence engine

The grade is weak and disputed because the three largest randomized trials flatly disagree. REDUCE-IT (PMID 30415628) found a striking 25% drop in major cardiac events (HR 0.75) but only in patients with high triglycerides and established disease already on statins, using 4 g/day of prescription purified EPA. By contrast, VITAL (PMID 37836519), testing 1 g/day in the general population, showed no benefit for its primary endpoint (HR 0.92), and STRENGTH (PMID 33190147), using a 4 g/day EPA+DHA mix, was stopped for futility (HR 0.99).

Two meta-analyses temper, rather than resolve, the picture. A 149,051-person analysis (PMID 34505026) found only small reductions in CV mortality (RR 0.93) and non-fatal heart attack (RR 0.87) — with EPA-only formulas faring better — while flagging a higher atrial-fibrillation risk (RR 1.26). An updated review (PMID 36378553) likewise found a modest cut in coronary events (RR 0.91) but no stroke benefit.

Regulators and clinics mirror this split. The FDA grants only a qualified claim and EFSA cites 250 mg/day for normal cardiac function, yet the UK NHS steers people toward eating fish rather than capsules. Cleveland Clinic states supplements lower triglycerides but not cardiovascular risk, Harvard Health finds 'no evidence of heart-related benefits,' and even the more permissive AHA calls supplementation only 'reasonable' for secondary prevention — supporting a C, not a stronger grade.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.41
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Disputed
Confidence
84%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.34
L2 PubMedPrimary literature
0.45
L3 MechanismPlausibility
0.45
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.412
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 1 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis
PMID: 34505026 2021 統合分析 n = 149,051
Finding: Omega-3 reduced CV mortality (RR 0.93, p=0.01) and non-fatal MI (RR 0.87, p=0.0001); EPA monotherapy superior; AF risk increased (RR 1.26, p<0.05).
🟢 High quality Academic Effect size: [object Object]
View on PubMed
VITAL trial: Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
PMID: 37836519 2023 RCT (double-blind) n = 25,871
Finding: No significant reduction in major CVD events (HR 0.92, 95% CI 0.80-1.06); secondary benefit for total MI (HR 0.72, 95% CI 0.59-0.90).
🟢 High quality Government Effect size: [object Object]
View on PubMed
REDUCE-IT: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
PMID: 30415628 2019 RCT (double-blind) n = 8,179
Finding: Strong reduction in primary MACE: 17.2% vs 22.0% placebo (HR 0.75, 95% CI 0.68-0.83, p<0.001); CV death HR 0.80 (p=0.03).
🟢 High quality ⚠️ Industry-funded Effect size: [object Object]
View on PubMed
STRENGTH: Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Statin-Treated Patients
PMID: 33190147 2020 RCT (double-blind) n = 13,078
Finding: Null result: 12.0% vs 12.2% placebo (HR 0.99, 95% CI 0.90-1.09, p=0.84); trial terminated for futility; AF risk increased.
🟢 High quality ⚠️ Industry-funded Effect size: [object Object]
View on PubMed
Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence
PMID: 36378553 2022 系統性回顧 n = 127,477
Finding: Updated MA shows significant CHD event reduction (RR 0.91, 95% CI 0.85-0.97) and total MI reduction (RR 0.87, 95% CI 0.80-0.96); no stroke benefit; effects dose-dependent.
🟢 High quality Academic Effect size: [object Object]
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
Generally Recognized As Safe (GRAS) - authorized under 21 CFR 184.1472 source↗
L4b EU EFSA
Supportive
intakes of 250mg a day sufficient for normal cardiac function source↗
L4c UK NHS
Neutral
at least 2 portions of fish a week, including 1 of oily fish source↗
L4d TW TFDA / 衛福部
Supportive
每日攝取量所含之ω-3脂肪酸至少應達一.○克 source↗
L4e WHO
Neutral
2 g/day of purified omega-3 fatty acids offer substantial advantages source↗
L5a NIH Office of Dietary Supplements
Supportive
ALA is an essential fatty acid source↗
L5b Mayo Clinic
Cautious
omega-3 fatty acids are good for the heart source↗
L5c Cleveland Clinic
Against
fish oil supplements only to lower triglycerides, not cardiovascular risk source↗
L5d Harvard Health
Cautious
no evidence of heart-related benefits source↗
L5e Specialty Society (condition-mapped)
Cautious
treatment with n-3 PUFA supplements is reasonable source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-cardiovascular-disease-INT-omega-3-fatty-acids-001 繁體中文版 →